Ken Griffin Harrow Health, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Harrow Health, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 223,400 shares of HROW stock, worth $7.56 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

223,400

Previous 195,200 14.45%

Holding current value

$7.56 Million

Previous $4.08 Million 146.36%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$20.85 - $46.47 $36,883 - $82,205	1,769 Added 1.26%	142,001 $6.38 Million
Q2 2024 Aug 14, 2024	SELL	$10.0 - $21.64 $2 Million - $4.33 Million	-200,033 Reduced 58.79%	140,232 $2.93 Million
Q1 2024 May 15, 2024	BUY	$9.3 - $13.23 $1.47 Million - $2.1 Million	158,557 Added 87.26%	340,265 $4.5 Million
Q4 2023 Feb 14, 2024	SELL	$8.1 - $16.36 $1.21 Million - $2.44 Million	-149,223 Reduced 45.09%	181,708 $2.04 Million
Q3 2023 Nov 14, 2023	BUY	$14.03 - $22.08 $3.98 Million - $6.26 Million	283,667 Added 600.18%	330,931 $4.76 Million
Q2 2023 Aug 14, 2023	BUY	$17.37 - $28.08 $409,115 - $661,368	23,553 Added 99.33%	47,264 $899,000
Q1 2023 May 15, 2023	SELL	$13.84 - $21.46 $463,861 - $719,253	-33,516 Reduced 58.57%	23,711 $501,000
Q4 2022 Feb 14, 2023	BUY	$10.28 - $14.78 $588,293 - $845,815	57,227 New	57,227 $844,000
Q2 2022 Aug 15, 2022	BUY	$5.75 - $7.74 $56,039 - $75,434	9,746 Added 66.45%	24,413 $178,000
Q1 2022 May 16, 2022	SELL	$6.77 - $8.66 $17,757 - $22,715	-2,623 Reduced 15.17%	14,667 $100,000
Q3 2021 Nov 15, 2021	SELL	$6.99 - $10.6 $44,896 - $68,083	-6,423 Reduced 27.09%	17,290 $157,000
Q2 2021 Aug 16, 2021	SELL	$6.68 - $11.07 $4,321 - $7,162	-647 Reduced 2.66%	23,713 $220,000
Q2 2020 Aug 14, 2020	SELL	$3.61 - $6.47 $21,804 - $39,078	-6,040 Reduced 19.87%	24,360 $127,000
Q1 2020 May 15, 2020	BUY	$3.5 - $7.31 $47,481 - $99,167	13,566 Added 80.59%	30,400 $116,000
Q4 2019 Feb 14, 2020	SELL	$4.6 - $7.88 $7,571 - $12,970	-1,646 Reduced 8.91%	16,834 $131,000
Q2 2019 Aug 14, 2019	SELL	$4.2 - $8.7 $60,509 - $125,340	-14,407 Reduced 43.81%	18,480 $160,000
Q1 2019 May 15, 2019	BUY	$4.75 - $7.1 $156,213 - $233,497	32,887 New	32,887 $0

Others Institutions Holding HROW

# of Institutions

176

Shares Held

21.4M

Call Options Held

845K

Put Options Held

717K

View Full List

About HARROW HEALTH, INC.

Ticker HROW
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 27,070,000
Market Cap $916M
Description
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company tha...

More about HROW

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account